Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 122

1.

The blood-brain barrier is intact after levodopa-induced dyskinesias in parkinsonian primates--evidence from in vivo neuroimaging studies.

Astradsson A, Jenkins BG, Choi JK, Hallett PJ, Levesque MA, McDowell JS, Brownell AL, Spealman RD, Isacson O.

Neurobiol Dis. 2009 Sep;35(3):348-51. doi: 10.1016/j.nbd.2009.05.018. Epub 2009 Jun 6.

2.

Changes in glutamate receptors in dyskinetic parkinsonian monkeys after unilateral subthalamotomy.

Jourdain VA, Morin N, Grégoire L, Morissette M, Di Paolo T.

J Neurosurg. 2015 Dec;123(6):1383-93. doi: 10.3171/2014.10.JNS141570. Epub 2015 May 1.

PMID:
25932606
3.

α7 nicotinic receptor agonists reduce levodopa-induced dyskinesias with severe nigrostriatal damage.

Zhang D, McGregor M, Bordia T, Perez XA, McIntosh JM, Decker MW, Quik M.

Mov Disord. 2015 Dec;30(14):1901-1911. doi: 10.1002/mds.26453. Epub 2015 Nov 17.

4.

Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.

Tamim MK, Samadi P, Morissette M, Grégoire L, Ouattara B, Lévesque D, Rouillard C, Di Paolo T.

Neuropharmacology. 2010 Jan;58(1):286-96. doi: 10.1016/j.neuropharm.2009.06.030. Epub 2009 Jul 2.

PMID:
19576910
5.

Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.

Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.

Brain. 2008 Dec;131(Pt 12):3380-94. doi: 10.1093/brain/awn235. Epub 2008 Oct 24.

PMID:
18952677
6.

L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.

Ando K, Inoue T, Itoh T.

Pharmacol Biochem Behav. 2014 Dec;127:62-9. doi: 10.1016/j.pbb.2014.10.009. Epub 2014 Oct 31.

PMID:
25449794
7.

Antidyskinetic effect of magnesium sulfate in MPTP-lesioned monkeys.

Chassain C, Eschalier A, Durif F.

Exp Neurol. 2003 Aug;182(2):490-6.

PMID:
12895461
8.

Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.

Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.

Parkinsonism Relat Disord. 2009 Jul;15(6):445-52. doi: 10.1016/j.parkreldis.2008.11.001. Epub 2009 Feb 3.

PMID:
19196540
9.

Brain 5-HT(2A) receptors in MPTP monkeys and levodopa-induced dyskinesias.

Riahi G, Morissette M, Parent M, Di Paolo T.

Eur J Neurosci. 2011 May;33(10):1823-31. doi: 10.1111/j.1460-9568.2011.07675.x. Epub 2011 Apr 19.

PMID:
21501255
10.
11.
12.

Vascular endothelial growth factor is upregulated by L-dopa in the parkinsonian brain: implications for the development of dyskinesia.

Ohlin KE, Francardo V, Lindgren HS, Sillivan SE, O'Sullivan SS, Luksik AS, Vassoler FM, Lees AJ, Konradi C, Cenci MA.

Brain. 2011 Aug;134(Pt 8):2339-57. doi: 10.1093/brain/awr165. Epub 2011 Jul 19.

13.

The acute antiparkinsonian and antidyskinetic effect of AFQ056, a novel metabotropic glutamate receptor type 5 antagonist, in L-Dopa-treated parkinsonian monkeys.

Grégoire L, Morin N, Ouattara B, Gasparini F, Bilbe G, Johns D, Vranesic I, Sahasranaman S, Gomez-Mancilla B, Di Paolo T.

Parkinsonism Relat Disord. 2011 May;17(4):270-6. doi: 10.1016/j.parkreldis.2011.01.008. Epub 2011 Feb 15.

PMID:
21315648
14.

Striatal Akt/GSK3 signaling pathway in the development of L-Dopa-induced dyskinesias in MPTP monkeys.

Morissette M, Samadi P, Hadj Tahar A, Bélanger N, Di Paolo T.

Prog Neuropsychopharmacol Biol Psychiatry. 2010 Apr 16;34(3):446-54. doi: 10.1016/j.pnpbp.2009.12.011. Epub 2009 Dec 16.

PMID:
20026151
15.

Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys.

Morin N, Grégoire L, Gomez-Mancilla B, Gasparini F, Di Paolo T.

Neuropharmacology. 2010 Jun;58(7):981-6. doi: 10.1016/j.neuropharm.2009.12.024. Epub 2010 Jan 13.

PMID:
20074579
16.

Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia.

Aubert I, Guigoni C, Li Q, Dovero S, Bioulac BH, Gross CE, Crossman AR, Bloch B, Bezard E.

Biol Psychiatry. 2007 Apr 1;61(7):836-44. Epub 2006 Sep 1.

PMID:
16950226
17.

Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys.

Cao X, Liang L, Hadcock JR, Iredale PA, Griffith DA, Menniti FS, Factor S, Greenamyre JT, Papa SM.

J Pharmacol Exp Ther. 2007 Oct;323(1):318-26. Epub 2007 Jul 13.

18.

L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice.

Suárez LM, Solís O, Caramés JM, Taravini IR, Solís JM, Murer MG, Moratalla R.

Biol Psychiatry. 2014 May 1;75(9):711-22. doi: 10.1016/j.biopsych.2013.05.006. Epub 2013 Jun 13.

PMID:
23769604
19.

Naltrexone in the short-term decreases antiparkinsonian response to l-Dopa and in the long-term increases dyskinesias in drug-naïve parkinsonian monkeys.

Samadi P, Grégoire L, Hadj Tahar A, Di Paolo T, Rouillard C, Bédard PJ.

Neuropharmacology. 2005 Aug;49(2):165-73. Epub 2005 Mar 29.

PMID:
15996565
20.

Repeated administration of piribedil induces less dyskinesia than L-dopa in MPTP-treated common marmosets: a behavioural and biochemical investigation.

Smith LA, Tel BC, Jackson MJ, Hansard MJ, Braceras R, Bonhomme C, Chezaubernard C, Del Signore S, Rose S, Jenner P.

Mov Disord. 2002 Sep;17(5):887-901.

PMID:
12360537

Supplemental Content

Support Center